Evaluation of alpha-methylacyl-CoA racemase, metallothionein and prostate specific antigen as prostate cancer prognostic markers
Language English Country Slovakia Media print
Document type Comparative Study, Evaluation Study, Journal Article, Research Support, Non-U.S. Gov't
PubMed
22248277
DOI
10.4149/neo_2012_025
Knihovny.cz E-resources
- MeSH
- Adenocarcinoma genetics metabolism pathology MeSH
- Adult MeSH
- Real-Time Polymerase Chain Reaction MeSH
- Middle Aged MeSH
- Humans MeSH
- RNA, Messenger genetics MeSH
- Metallothionein genetics metabolism MeSH
- Biomarkers, Tumor genetics metabolism MeSH
- Prostatic Neoplasms genetics metabolism pathology MeSH
- Prognosis MeSH
- Prostate-Specific Antigen genetics metabolism MeSH
- Racemases and Epimerases genetics metabolism MeSH
- Aged MeSH
- Case-Control Studies MeSH
- Neoplasm Grading MeSH
- Blotting, Western MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Publication type
- Journal Article MeSH
- Evaluation Study MeSH
- Research Support, Non-U.S. Gov't MeSH
- Comparative Study MeSH
- Names of Substances
- alpha-methylacyl-CoA racemase MeSH Browser
- RNA, Messenger MeSH
- Metallothionein MeSH
- MT1A protein, human MeSH Browser
- MT2A protein, human MeSH Browser
- Biomarkers, Tumor MeSH
- Prostate-Specific Antigen MeSH
- Racemases and Epimerases MeSH
Current diagnostic techniques are inefficient in distinguishing latent and low-risk forms of prostate cancer from high-risk forms. The present study is focused on determination of putative tumor markers of aggressive high-grade forms of prostate cancer. Potential markers were determined in blood sera of 133 patients (82 cases and 51 controls) and in cell lines (Gleason score 9-derived 22Rv1 and normal tissue derived PNT1A) on mRNA and protein levels. Alpha-methylacyl-CoA racemase (AMACR), metallothionein classes 1A and 2A (MT1A and MT2A) were determined and compared to prostate specific antigen (PSA) levels. On mRNA level, significantly increased expression of MT2A (2.4-fold), PSA (2.6-fold) and AMACR (8.4-fold) and insignificantly (1.9-fold) elevated MT1A in 22Rv1 compared to non-tumor PNT1A were determined. On protein level, significant enhancement of free PSA and total PSA in tumor cell line was evident. AMACR protein was 1.5-fold elevated in tumor line (below the level of significance). Contrary to mRNA, significantly (p = 0.01) reduced level of MT protein in tumor lines was determined. In the case of serum level, significantly enhanced MT level (4.5-fold) in patients' sera was found. No significant changes were observed in the case of AMACR. These findings indicate possible alternative role of MT to PSA prostate cancer marker. In addition, level of AMACR is distinctly higher in the Gleason score 9 in serum of patients and MT shows a descending trend in relation to Gleason score.
References provided by Crossref.org
Metallothionein - immunohistochemical cancer biomarker: a meta-analysis
Serum metallothioneins in childhood tumours-a potential prognostic marker
